News
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.
The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...
The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...
Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...
The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high ...
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback